Document Type
Article
Publication Date
2017
Abstract
The Trans-Pacific Partnership Agreement’s many provisions that were beneficial to the pharmaceutical industry have caused a good deal of controversy. Specifically, critics allege that the TPP’s provisions requiring that member states expand patentable subject matter, adjust pharmaceutical patent terms, and link regulatory marketing approval to a drug's patent status would have raised drug prices and hindered access to medicines, particularly in developing countries. Closer examination of these provisions as well as the various ways in which member states can modify or ameliorate the effects of these provisions suggests that their potential effect on drug prices and access to health care is not nearly so clear, however.
Publication Title
Southern Methodist University Science and Technology Law Review
Article Number
1081
Suggested Bluebook Citation
Much Ado About the TPP’s Effect on Pharmaceuticals, __ J. ECON. L. & MGMT. __ (symposium issue) (forthcoming)
Included in
Intellectual Property Law Commons, International Law Commons, International Trade Law Commons